Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-23T02:38:51.146Z Has data issue: false hasContentIssue false
  • English
  • Français

Montelukast and worsening of hallucinations in paranoid schizophrenia

Published online by Cambridge University Press:  02 January 2018

Nithya Anandan  and
Fade Ibitoye
Nithya Anandan
Affiliation:
5 Boroughs Partnership NHS Trust, Whiston Hospital Warrington Road, Prescot, Merseyside L35 5DR, email: [email protected]
Fade Ibitoye
Affiliation:
5 Boroughs Partnership NHS Trust, Whiston Hospital Warrington Road, Prescot, Merseyside L35 5DR
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
The columns
Information
Psychiatric Bulletin , Volume 32 , Issue 7 , July 2008 , pp. 276
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2008

References

Netherlands Pharmacovigilance Centre (2007) Montelukast and Depressive Symptoms. Netherlands Pharmacovigilance Centre (http://www.lareb.nl/documents/kwb_2006_4_montel.pdf).Google Scholar
Price, D. (2000) Tolerability of montelukast. Drugs, 59 (suppl 1), 35–42.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.